New York

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Hidradenitis suppurativa3 trials
• Schizophrenia2 trials
• Alzheimer disease1 trial

Phase

• Phase 33 trials
• Phase 22 trials

Status

• Completed2 trials
• Recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• MoonLake Immunotherapeutics AG3 trials
• MapLight Therapeutics2 trials

Running trials

• Recruiting

  A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

  NCT07459647· Phase 2· MapLight Therapeutics· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

  NCT06887192· Phase 2· MapLight Therapeutics· Source

• Enrolling by invitation

  A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT07007637· Phase 3· MoonLake Immunotherapeutics AG· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia2 recruiting
• Alzheimer disease1 recruiting
• Hidradenitis suppurativa1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06411899· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06411379· Phase 3· MoonLake Immunotherapeutics AG· Source